Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TMS Co., Ltd. ( (JP:4891) ) has provided an update.
TMS Co., Ltd. announced a resolution to distribute a portion of the dividend received from Corxel Pharmaceuticals Limited to original intellectual property right holders. This payment, amounting to up to 69 million yen, is based on patent assignment contracts and internal rules, and will be recorded as non-operating expenses in the financial statements for the fiscal year ending February 28, 2025. The timing and exact amount of the distribution are still under discussion, but this move reflects TMS’s commitment to honoring its contractual obligations and maintaining transparency with stakeholders.
More about TMS Co., Ltd.
TMS Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the discovery and development of transformative medicines for serious diseases with high unmet medical needs. The company’s pipeline features small molecule compounds known as SMTPs, derived from a fungus, and includes programs targeting acute ischemic stroke, resistant hypertension, acute kidney injury, and spinal cord injury. TMS collaborates with leading academic institutions in Japan to bridge academic discoveries with the global pharmaceutical market.
YTD Price Performance: -4.13%
Average Trading Volume: 1,735,106
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen8.43B
For a thorough assessment of 4891 stock, go to TipRanks’ Stock Analysis page.